Current and emerging treatments in the management of castration-resistant prostate cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N. Engl. J. Med.357(26), 2696–2705 (2007).
   PubMed Web of Science ®Google Scholar
• Fu Q, Moul JW, Sun L. Contemporary radical prostatectomy. Prostate Cancer2011, 645030 (2011).
   Google Scholar
• Hammad FT. Radical prostatectomy. Ann. NY Acad. Sci.1138, 267–277 (2008).
   Google Scholar
• DeVita V, Lawrence TS, Rosenberg, SA. DeVita, Hellman, and Rosenberg’s Cancer Principles and Practice of Oncology. Wolters Kluwer Health/Lippincott Williams and Wilkins, PA, USA (2011).
   Google Scholar
• Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer88(12 Suppl.), 2989–2994 (2000).
   PubMedGoogle Scholar
• Pentyala SN, Lee J, Hsieh K et al. Prostate cancer: a comprehensive review. Med. Oncol.17(2), 85–105 (2000).
   PubMed Web of Science ®Google Scholar
• Beltran H, Beer TM, Carducci MA et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur. Urol.60(2), 279–290 (2011).
   PubMed Web of Science ®Google Scholar
• Harzstark AL, Small EJ. Castrate-resistant prostate cancer: therapeutic strategies. Expert Opin. Pharmacother.11(6), 937–945 (2010).
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Kattan MW, Eastham JA et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol.27(26), 4300–4305 (2009).
   PubMed Web of Science ®Google Scholar
• Alicikus ZA, Yamada Y, Zhang Z et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer117(7), 1429–1437 (2011).
   PubMed Web of Science ®Google Scholar
• Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J. Urol.172(3), 910–914 (2004).
   PubMed Web of Science ®Google Scholar
• Sharifi N. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Expert Opin. Investig. Drugs19(7), 837–846 (2010).
   PubMed Web of Science ®Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol.23(32), 8253–8261 (2005).
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med.339(15), 1036–1042 (1998).
   PubMed Web of Science ®Google Scholar
• Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med.321(7), 419–424 (1989).
   PubMed Web of Science ®Google Scholar
• Mousses S, Wagner U, Chen Y et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene20(46), 6718–6723 (2001).
   PubMed Web of Science ®Google Scholar
• Leversha MA, Han J, Asgari Z et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin. Cancer Res.15(6), 2091–2097 (2009).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24(19), 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16), 3670–3679 (2009).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol.28(7), 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr. Opin. Oncol.21(3), 260–265 (2009).
   PubMed Web of Science ®Google Scholar
• Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J. Urol.168(6), 2439–2443 (2002).
   PubMed Web of Science ®Google Scholar
• Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br. J. Cancer95(7), 767–774 (2006).
   PubMed Web of Science ®Google Scholar
• Ripple GH, Wilding G. Drug development in prostate cancer. Semin. Oncol.26(2), 217–226 (1999).
   PubMed Web of Science ®Google Scholar
• Smith DC. Chemotherapy for hormone refractory prostate cancer. Urol. Clin. North Am26(2), 323–331 (1999).
   Google Scholar
• Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol.14(6), 1756–1764 (1996).
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res.13(21), 6396–6403 (2007).
   PubMed Web of Science ®Google Scholar
• Mita AC, Denis LJ, Rowinsky EK et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res.15(2), 723–730 (2009).
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet376(9747), 1147–1154 (2010).
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol.28(9), 1481–1488 (2010).
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Judson I, Dowsett M et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer90(12), 2317–2325 (2004).
   PubMed Web of Science ®Google Scholar
• Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J. Steroid Biochem. Mol. Biol.84(5), 555–562 (2003).
   Google Scholar
• de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med.364(21), 1995–2005 (2011).
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol.28(9), 1489–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol.28(9), 1496–1501 (2010).
   PubMed Web of Science ®Google Scholar
• Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat. Biotechnol.27(2), 129–139 (2009).
   PubMed Web of Science ®Google Scholar
• Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J. Clin. Oncol.17(6), 1654–1663 (1999).
   PubMed Web of Science ®Google Scholar
• Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin. Oncol.21(5), 630–656 (1994).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst.94(19), 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst.96(11), 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized Phase II trial. J. Urol.182(2), 509–515; discussion 515–506 (2009).
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med.361(8), 745–755 (2009).
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a Phase 3, randomised, placebo-controlled trial. Lancet379(9810), 39–46 (2012).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet377(9768), 813–822 (2011).
   PubMed Web of Science ®Google Scholar
• Biersack HJ, Palmedo H, Andris A et al. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J. Nucl. Med.52(11), 1721–1726 (2011).
   PubMed Web of Science ®Google Scholar
• Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol.16(4), 1574–1581 (1998).
   PubMed Web of Science ®Google Scholar
• Sciuto R, Festa A, Rea S et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J. Nucl. Med.43(1), 79–86 (2002).
   PubMed Web of Science ®Google Scholar
• Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised Phase II trial. Lancet357(9253), 336–341 (2001).
   PubMed Web of Science ®Google Scholar
• Morris MJ, Pandit-Taskar N, Carrasquillo J et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J. Clin. Oncol.27(15), 2436–2442 (2009).
   PubMed Web of Science ®Google Scholar
• Bhandari MS, Hussain M. Epothilones and the next generation of Phase III trials for prostate cancer. BJU Int.96(3), 296–302 (2005).
   Google Scholar
• Chi KN, Beardsley E, Eigl BJ et al. A Phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann. Oncol.23(1), 53–58 (2011).
   Google Scholar
• Harzstark AL, Rosenberg JE, Weinberg VK et al. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a Phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer doi:10.1002/cncr.25810 (2010) (Epub ahead of print).
   Google Scholar
• Wosikowski K, Lamphere L, Unteregger G et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother. Pharmacol.60(4), 589–600 (2007).
   PubMed Web of Science ®Google Scholar
• Latif T, Wood L, Connell C et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest. New Drugs23(1), 79–84 (2005).
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324(5928), 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet375(9724), 1437–1446 (2010).
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the Phase III AFFIRM study. J. Clin. Oncol.30(Suppl. 5), (2012) (Abstract LBA1).
   Web of Science ®Google Scholar
• Kaku T, Hitaka T, Ojida A et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg. Med. Chem.19(21), 6383–6399 (2011).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T, Stadler WM. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a Phase I/II, open-label study [abstract]. J. Clin. Oncol.28(Suppl.), 15S (2010).
   Google Scholar
• Eisner JR, Abbott DH, Bird IM, Rafferty SW, Moore MR, Schotzinger RJ. VT-464: a novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC). J. Clin. Oncol.30(Suppl. 5), (2012) (Abstract 198).
   Google Scholar
• Pisle ST, Pressler HM, Troutman SM et al. Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model. J. Clin. Oncol.30(Suppl. 5), (2012) (Abstract 64).
   Google Scholar
• Sanda MG, Ayyagari SR, Jaffee EM et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol.151(3), 622–628 (1994).
   PubMed Web of Science ®Google Scholar
• Harzstark AL, Small EJ. Immunotherapeutics in development for prostate cancer. Oncologist14(4), 391–398 (2009).
   PubMed Web of Science ®Google Scholar
• Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med.353(12), 1224–1235 (2005).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Oh WK. Castration-resistant prostate cancer: new science and therapeutic prospects. Ther. Adv. Med. Oncol.2(3), 189–207 (2010).
   Google Scholar
• Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res.13(6), 1810–1815 (2007).
   PubMed Web of Science ®Google Scholar
• Fong L, Kwek SS, O’Brien S et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res.69(2), 609–615 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Q, Diao X, Sun J, Chen Z. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Urol. Oncol. doi:10.1016/j.urolonc.2011.01.006 (2011) (Epub ahead of print).
   Google Scholar
• George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res.7(7), 1932–1936 (2001).
   PubMed Web of Science ®Google Scholar
• Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology54(3), 523–527 (1999).
   PubMed Web of Science ®Google Scholar
• Ning YM, Gulley JL, Arlen PM et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol.28(12), 2070–2076 (2010).
   PubMed Web of Science ®Google Scholar
• Picus J, Halabi S, Kelly WK et al. A Phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer117(3), 526–533 (2011).
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Carducci M et al. Randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol.30(13), 1534–1540 (2012).
   PubMed Web of Science ®Google Scholar
• Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J. Chin. Med. Assoc.73(9), 449–456 (2010).
   PubMed Web of Science ®Google Scholar
• Tew WP, Gordon M, Murren J et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin. Cancer Res.16(1), 358–366 (2010).
   PubMed Web of Science ®Google Scholar
• Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate67(7), 790–797 (2007).
   PubMed Web of Science ®Google Scholar
• Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol. Cancer9, 107 (2010).
   PubMed Web of Science ®Google Scholar
• Pili R, Haggman M, Stadler WM et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J. Clin. Oncol.29(30), 4022–4028 (2011).
   PubMed Web of Science ®Google Scholar
• Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a Phase II randomized discontinuation trial. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 4516).
   Google Scholar
• Beardsley EK, Hotte SJ, North S et al. A Phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest. New Drugs doi:10.1007/s10637-011-9722-5 (2011) (Epub ahead of print).
   Google Scholar
• Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer113(1), 193–201 (2008).
   PubMed Web of Science ®Google Scholar
• Yu EY, Wilding G, Posadas E et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res.15(23), 7421–7428 (2009).
   PubMed Web of Science ®Google Scholar
• Yu EY, Massard C, Gross ME et al. Once-daily dasatinib: expansion of Phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology77(5), 1166–1171 (2011).
   PubMed Web of Science ®Google Scholar
• Araujo JC, Mathew P, Armstrong AJ et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a Phase 1–2 study. Cancer118(1), 63–71 (2012).
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol.21(2), 319–324 (2010).
   PubMed Web of Science ®Google Scholar
• Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled Phase II study. Lancet Oncol.8(7), 587–594 (2007).
   PubMed Web of Science ®Google Scholar
• Parker C, Heinrich D, O’Sullivan JM et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha pharmaceutical: Results from a Phase III randomized trial (ALYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J. Clin. Oncol.30(Suppl. 5), (2012) (Abstract 8).
   Google Scholar
• Sartor AO, Heinrich D, Helle SI et al. Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a Phase III randomized trial (ALSYMPCA). J. Clin. Oncol.30(Suppl. 5), (2012) (Abstract 9).
   Google Scholar
• Sartor O, Reid RH, Hoskin PJ et al. Samarium-153–Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology63(5), 940–945 (2004).
   PubMed Web of Science ®Google Scholar
• Lewington VJ, McEwan AJ, Ackery DM et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur. J. Cancer27(8), 954–958 (1991).
   PubMed Web of Science ®Google Scholar